A qualitative inquiry into methadone maintenance treatment for opioid-dependent prisoners in Tehran, Iran

References 

1. Bayanzadeh SA, Afshar P. A study of effectiveness of pharmacological and psychological interventions in reducing drug related harms and improving psychological status of drug dependent prisoners. Tehran: Tehran Psychiatric Institute, Iran Prison Organization, and United Nations Office on Drugs and Crime, Iran; 2004;(in Persian)
2. Beyrer C, Jittiwutikarn J, Teokul W, Razak MH, Suriyanon V, Srirak N, et al. Drug use, increasing incarceration rates, and prison-associated HIV risks in Thailand. AIDS and Behavior. 2003;7(2):153–161
   • MEDLINE
   • CrossRef
3. Bolhari J, Alvandi M, Afshar P, Bayanzadeh A, Rezaii M, Rahimi Movaghar A. Assessment of drug abuse in Iranian prisons. Tehran: United Nations Drug Control Programme (UNDCP), Iran and Drug Control Headquarters (DCHQ) in Iran; 2002;(in Persian)
4. Dolan KA, Wodak A. HIV transmission in a prison system in an Australian state. The Medical Journal of Australia. 1999;171(1):14–17
   • MEDLINE
5. Dolan KA, Shearer J, MacDonald M, Mattick RP, Hall W, Wodak AD. A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug and Alcohol Dependence. 2003;72(1):59–65
   • Abstract
   • Full Text
   • Full-Text PDF (200 KB)
   • CrossRef
6. Dolan KA, Shearer J, White B, Zhou J, Kaldor J, Wodak AD. Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction. 2005;100(6):820–828
   • MEDLINE
   • CrossRef
7. Farnia M, Afshar P. An overview on HIV/AIDS in prisons of Islamic Republic of Iran. Tehran: Health and Treatment Headquarter, Iran Prison Organization; 2006;(in Persian)
8. Farrel M, Gowing L, Marsden J, Ling W, Ali R. Effectiveness of drug dependence treatment in HIV prevention. International Journal of Drug Policy. 2005;16S:67–75
9. Gossop M, Marsden J, Stewart D, Treacy S. Outcomes after methadone maintenance and methadone reduction treatments: Two-year follow-up results from the National Treatment Outcome Research Study. Drug and Alcohol Dependence. 2001;62(3):255–264
   • Abstract
   • Full Text
   • Full-Text PDF (102 KB)
   • CrossRef
10. Larney S, Dolan K. A literature review of international implementation of opioid substitution treatment in prisons: Equivalence of care?. European Addiction Research. 2009;15(2):107–112
    • CrossRef
11. Macalino GE, Vlahov D, Sanford-Colby S, Patel S, Sabin K, Salas C, et al. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. American Journal of Public Health. 2004;94(7):1218–1223
    • MEDLINE
    • CrossRef
12. Pope C, Ziebland S, Mays N. Analysing qualitative data. In:  Pope C,  Mays N editor. Qualitative research in health care. London: BMJ Books; 2001;p. 75–88
13. Razzaghi EM, Rahimi MA. Injection drug use in Tehran. Iran: Tehran University of Medical Sciences; 2005;
14. Razzaghi EM, Rahimi MA, Hoseini M, Madani S, Mohammad K. Rapid assessment of drug misuse in Tehran, Iran. Iran: Iranian Welfare Organization; 2000;
15. Ritchie J, Spencer L, O’Connor W. Carrying out qualitative analysis. In:  Ritchie J,  Lewis J editor. Qualitative research practice: A guide for social science students and researchers. London: SAGE Publications Ltd.; 2004;p. 219–262
16. Stark K, Bienzle U, Vonk R, Guggenmoos-Holzmann I. History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection among injecting drug users in Berlin. International Journal of Epidemiology. 1997;26(6):1359–1366
    • MEDLINE
    • CrossRef
17. Taylor A, Goldberg D, Emslie J, Wrench J, Gruer L, Cameron S, et al. Outbreak of HIV infection in a Scottish prison. British Medical Journal. 1995;310(6975):289–292
18. Tomasino V, Swanson AJ, Nolan J, Shuman HI. The key extended entry program (KEEP): A methadone treatment program for opiate-dependent inmates. The Mount Sinai Journal of Medicine. 2001;68(1):14–20
19. UNAIDS. (2006). Islamic Republic of Iran Country report on monitoring of the United Nations general assembly special session on HIV and AIDS declaration of commitment. Office of the Under-secretary for Health, Ministry of Health and Medical Education, Centre for Diseases Management. Retrieved March 3, 2009, from http://data.unaids.org/pub/Report/2006/2006_country_progress_report_iran_en.pdf?preview=true.
20. Vanichseni S, Kitayaporn D, Mastro TD, Mock PA, Raktham S, Des Jarlais DC, et al. Continued high HIV-1 incidence in a vaccine trial preparatory cohort of injection drug users in Bangkok, Thailand. AIDS. 2001;15(3):397–405
    • MEDLINE
    • CrossRef
21. WHO/UNODC/UNAIDS. (2004). Substitution maintenance treatment in the management of opioid dependence and HIV/AIDS prevention: Position paper. Geneva: World Health Organization, United Nations Office on Drugs and Crime, Joint United Nations Programme on HIV/AIDS.
22. Zamani S, Kihara M, Gouya MM, Vazirian M, Ono-Kihara M, Razzaghi EM, et al. Prevalence of and factors associated with HIV-1 infection among drug users visiting treatment centers in Tehran, Iran. AIDS. 2005;19(7):709–716
    • MEDLINE
23. Zamani S, Kihara M, Gouya MM, Vazirian M, Nassirimanesh B, Ono-Kihara M, et al. High prevalence of HIV infection associated with incarceration among community-based injecting drug users in Tehran, Iran. Journal of Acquired Immune Deficiency Syndromes. 2006;42(3):342–346
24. Zamani S, Ichikawa S, Nassirimanesh B, Vazirian M, Ichikawa K, Gouya MM, et al. Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. International Journal of Drug Policy. 2007;18(5):359–363